Immunic Names Elena Ridloff to Board of Directors
Immunic has appointed Elena Ridloff to its board of directors. The company said it expects top-line data from its Phase 3 ENSURE trials in relapsing multiple sclerosis by year-end and plans to begin a confirmatory Phase 3 program in progressive MS. Management said Ridloff’s biopharma experience will support efforts to advance vidofludimus calcium across MS patient populations.